IGF-I Molecule Synonym Name
IGF-I Protein Products
|Cat No||Species||Product Description|
|IG1-H4269||Human||Human IGF-I Protein, Fc Tag|
IGF-I Molecule Background
Insulin-like growth factor 1 (IGF-1) is also known as somatomedin C, IGF1A, IGFI, sulfation factor, and is a hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. A synthetic analog of IGF-1, mecasermin is used for the treatment of growth failure. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges. IGF-1 has a molecular weight of 7649 daltons. IGF-1 is produced primarily by the liver as an endocrine hormone as well as in target tissues in a paracrine/autocrine fashion. IGF-1 binds to at least two cell surface receptors: the Insulin-like growth factor 1 receptor, abbreviated as "IGF1R", and the insulin receptor. The IGF-1 receptor seems to be the "physiologic" receptor - it binds IGF-1 at significantly higher affinity than the IGF-1 that is bound to the insulin receptor. Like the insulin receptor, the IGF-1 receptor is a receptor tyrosine kinase - meaning it signals by causing the addition of a phosphate molecule on particular tyrosines. Its primary action is mediated by binding to its specific receptor IGF1R, present on many cell types in many tissues. Binding to the IGF1R, a receptor tyrosine kinase, initiates intracellular signaling; IGF-1 is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death. Insulin-like growth factor 1 has been shown to bind and interact with all the IGF-1 Binding Proteins (IGFBPs), of which there are six (IGFBP1-6). Specific references are provided for interactions with IGFBP3, IGFBP4 and IGFBP7.
- (1) SALMON WD Jr, et al., 1957, J Lab Clin Med 49 (6): 825–36.
- (2) Keating GM, et al., 2008, BioDrugs 22 (3): 177–88.
- (3) Horton JK, et al., 1989, Biochem. Pharmacol. 38 (11): 1727–36.
- (4) Ueki I, et al., 2000, Proc. Natl. Acad. Sci. U.S.A. 97 (12): 6868–73.
- (5) Buckway CK, et al., 2001, J. Clin. Endocrinol. Metab. 86 (10): 4943–50.
- (6) Qin X, et al., 1998, J. Biol. Chem. 273 (36): 23509–16.
- (7) Ahmed S, et al, 2003, Biochem. Biophys. Res. Commun. 310 (2): 612–8.